FDA Proposes to Reduce Regulatory Burden in the Development of Platform-Based Gene Therapy Using Genome Editing
Published 20 July 2026
Last update 22 July 2026
270
The FDA has published a draft guidance entitled "Utilization of Prior Knowledge in the Development of Gene Therapy Products Using Genome Editing."
In essence, the regulator proposes not to require the full generation of manufacturing, nonclinical, and clinical data for each new product if the developer can scientifically justify the applicability of knowledge already obtained for a similar technological platform.
🧬 Platform Approach
The key focus of the document is the use of platform data – information accumulated during the development of similar products, manufacturing processes, delivery systems, and genome editing technologies.
Sources of such data may include the company's previous programmes, CDMO and supplier data, scientific publications, pharmacopoeial standards, and joint industry initiatives.
⚙️ Manufacturing and Nonclinical Development
With regard to manufacturing and quality control, the FDA allows the use of previously validated analytical methods, stability data, comparability data, and process validation data. With sufficient platform similarity, this may reduce the scope of repeat studies and the number of manufacturing validation batches.
In the nonclinical part, it is proposed to make greater use of data on similar delivery systems, biodistribution, and toxicity.
At the same time, product-specific risks, primarily off-target editing and the effects of a particular guide RNA, still require separate assessment.
📊 Clinical Development
The clinical section is particularly significant.
Prior clinical experience may be used for dose selection, defining toxicity criteria, duration of follow-up, immunogenicity assessment, biomarkers, and other elements of study design.
In certain cases, previously collected data may allow for a reduction in the volume of new safety, efficacy, and clinical pharmacology data.
The FDA also emphasises the importance of natural history studies, real-world data, and shared databases that may be used by multiple developers.
⚖️ Data Extrapolation Is Not Automatic
The developer must justify the comparability of products and processes and, if necessary, provide additional confirmatory studies.
The FDA recommends discussing this approach as early as possible in the development process.
📌 Why This Matters for Rare Diseases
For orphan diseases, this approach is particularly important. Gene and cell technologies require risk-based regulation, as uniform requirements do not always align with the specific features of platform technologies and the development of therapies for small patient populations.
The FDA's approach demonstrates the possibility of flexible regulation and the elimination of unnecessary duplication of research.
This may accelerate the development of innovative therapies without compromising requirements for quality, safety, and efficacy – and ultimately improve access to treatment for patients with rare diseases.
📎 FDA Draft Guidance
In essence, the regulator proposes not to require the full generation of manufacturing, nonclinical, and clinical data for each new product if the developer can scientifically justify the applicability of knowledge already obtained for a similar technological platform.
🧬 Platform Approach
The key focus of the document is the use of platform data – information accumulated during the development of similar products, manufacturing processes, delivery systems, and genome editing technologies.
Sources of such data may include the company's previous programmes, CDMO and supplier data, scientific publications, pharmacopoeial standards, and joint industry initiatives.
⚙️ Manufacturing and Nonclinical Development
With regard to manufacturing and quality control, the FDA allows the use of previously validated analytical methods, stability data, comparability data, and process validation data. With sufficient platform similarity, this may reduce the scope of repeat studies and the number of manufacturing validation batches.
In the nonclinical part, it is proposed to make greater use of data on similar delivery systems, biodistribution, and toxicity.
At the same time, product-specific risks, primarily off-target editing and the effects of a particular guide RNA, still require separate assessment.
📊 Clinical Development
The clinical section is particularly significant.
Prior clinical experience may be used for dose selection, defining toxicity criteria, duration of follow-up, immunogenicity assessment, biomarkers, and other elements of study design.
In certain cases, previously collected data may allow for a reduction in the volume of new safety, efficacy, and clinical pharmacology data.
The FDA also emphasises the importance of natural history studies, real-world data, and shared databases that may be used by multiple developers.
⚖️ Data Extrapolation Is Not Automatic
The developer must justify the comparability of products and processes and, if necessary, provide additional confirmatory studies.
The FDA recommends discussing this approach as early as possible in the development process.
📌 Why This Matters for Rare Diseases
For orphan diseases, this approach is particularly important. Gene and cell technologies require risk-based regulation, as uniform requirements do not always align with the specific features of platform technologies and the development of therapies for small patient populations.
The FDA's approach demonstrates the possibility of flexible regulation and the elimination of unnecessary duplication of research.
This may accelerate the development of innovative therapies without compromising requirements for quality, safety, and efficacy – and ultimately improve access to treatment for patients with rare diseases.
📎 FDA Draft Guidance
